<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283983</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 097-13</org_study_id>
    <nct_id>NCT02283983</nct_id>
  </id_info>
  <brief_title>Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose</brief_title>
  <acronym>BANQUISE</acronym>
  <official_title>Evaluation of Cryoprotection of Nail Toxicity Induced by Docetaxel Low Cumulative Dose. Controlled, Randomized, Open, Multicentre Prospective.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the specific patient population studied receiving 5-Fluorouracil, epirubicin and
      cyclophosphamide - Docetaxel sequence (cumulative dose &lt;300 mg / m2), using a cryoprotection
      has never been assessed.

      The effectiveness of cryoprotection of onycholysis secondary to Docetaxel is not well
      established in this population (breast cancer in the adjuvant setting) and is based solely on
      a publication (Scotté) that does not contain the same therapeutic modalities (dose
      significantly higher). The few studies available have heterogeneous populations,
      nonrandomized, retrospective or with a small sample.

      By extension to what has been observed with higher cumulative doses of docetaxel, some teams
      offer mittens and booties chilled to their patients, a practice that is not the subject of a
      national consensus.

      The investigators wish to accurately assess the effectiveness of mittens and slippers
      chilled, their tolerance and their observance because of weak data on this specific
      population in the literature.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the occurrence of nail toxicity of grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 evaluated at 8 weeks post infusion of docetaxel.</measure>
    <time_frame>8 weeks post infusion of docetaxel</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">302</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Standard cryoprotection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proposal helmet without mittens and booties</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoprotection with mittens and booties</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cryoprotection with mittens and booties</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mittens and booties</intervention_name>
    <arm_group_label>Cryoprotection with mittens and booties</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cooling helmet</intervention_name>
    <arm_group_label>Standard cryoprotection</arm_group_label>
    <arm_group_label>Cryoprotection with mittens and booties</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  upper age to 18 years

          -  mammary adenocarcinoma nonmetastatic and histologically proven

          -  wait under an adjuvant or neoadjuvant chemotherapy according to the following
             conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100
             (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500
             or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3
             cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++

          -  Patient with the capacity/faculties to understand a newsletter and sign an informed
             consent

          -  Patient receiving social coverage

          -  Patient who can be treated and followed in the center for a period of at least one
             year

          -  WHO scale 0 or 1

        Exclusion Criteria:

          -  Age below 18 years

          -  Diseases of the scalp or whatever hair-showing against helmet or alopecia

          -  Using pre nail resin before and per chemotherapy

          -  mammary adenocarcinoma stage IV

          -  Indication of docetaxel for cancer of another organ than breast

          -  Treatment processing or programmed during chemotherapy with an innovative molecule
             being evaluated

          -  Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia.

          -  Uncontrolled severe arterial disease.

          -  Presence of a device&gt; grade 1 neuropathy before the start of chemotherapy

          -  Patient unable to submit the protocol followed for psychological, social, family or
             geographical

          -  Patient with an incompatible underlying disease or concomitant with the inclusion in
             the trial, whether psychiatric or somatic

          -  Patient trust, guardianship, under legal protection measure, deprived of freedom

          -  Male

          -  Criteria for non randomization (before the first course of docetaxel) :

               -  Presence of peripheral neuropathy&gt; grade 1 after the first 3 cycles of
                  5-Fluorouracil, epirubicin and cyclophosphamide 100.

               -  Presence of a nail or skin toxicity&gt; grade 1 after 3 cycles of 5-Fluorouracil,
                  epirubicin and cyclophosphamide 100.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank PRIOU, PH</last_name>
    <role>Study Director</role>
    <affiliation>CHD Vendee La Roche sur Yon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie AUZANNEAU, ARC</last_name>
    <phone>02 51 44 63 80</phone>
    <phone_ext>+33</phone_ext>
    <email>lucie.auzanneau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie ABADIE LACOURTOISIE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain ZANNETI, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank PRIOU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oana COJOCARASU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Régine LAMY, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude EL KOURI, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - Nantes</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuelle BOURBOULOUX, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valérie DELECROIX, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie Saint-Yves</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHBA Vannes</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

